Background
COVID-19 has been alarmingly spreading worldwide, with Brazil ranking third in total number of cases and second in deaths. Being a continental country, which comprises many ethnic groups and an engrained social inequality, the pandemic evidenced this heterogeneous discrepancy. We aimed to estimate the impact of associated risk factors, isolated or combined, on COVID-19 severeness, detecting specific epidemiological profiles for multiple age ranges in hospitalized Brazilians.
Methods In this large retrospective cohort study, we used open-access data from the Ministry of Health of Brazil with COVID-19 confirmed hospitalized patients annotated in SRAG system between February and August 2020, a total of 235555 entries. The association of COVID-19 death with socio-demographic and clinical characteristics was analysed and presented as odds ratios adjusted by confounding co-variables. We also presented marginal mean aOR values for high-order interactions either by or not another fixed level or condition. We kept all other variables in the multivariate logistic models in their mean values or equal proportions.
Findings Younger individuals with one or more comorbidities had an adjusted odds ratio up to four-fold compared to those without it, in the same age interval. Younger diabetic patients either self-declared as brown ethnicity (aOR 5·58, 95% CI 4·97-6·25; p<0·0001) or with some other associated comorbidities, mainly chronic hematologic disease (21·09, 13·64-32·6; p<0·0001) and obesity (aOR 21·7, 95% CI not calculated; p<0·0001), resulted in outstanding death risk. Age over 60, particularly over 90 (28·91, 24·5-34·11; p<0.001), usage of invasive ventilatory support (16·23, 14·05-18·75; p<0·001), admission to intensive care units (3·14, 2·82-3·48; p<0·001), multiple respiratory symptoms (3·24, 2·79-3·75; p<0·0001), black ethnicity (1·78, 1·52-2·07; p<0·05), and diagnosis previous to hospitalization (1·32, 1·19-1·47; p<0·05) were associated with higher death odds. As protective factors, with roughly one third less death risk, we found hospitalization duration of (4, 7] days and illness onset to hospitalization over 6 days.
Interpretation We found evidence for increased COVID-19 risk in two distinct groups: younger patients with prevalent comorbidities, especially in brown ethnicity, and patients with black ethnicity. We speculate that the pro-inflammatory synergism of COVID-19 and comorbidities, promoting an overproduction of cytokines, is partially the cause of higher mortality in this young group. Brazilian black and brown are underprivileged populations, with structural social inequality, limited healthcare access and, thus, remarkable disease vulnerability. Our study supplies essential data to patient stratification upon admission, optimizing hospital management, and to guide public policy determinations, including group prioritization for COVID-19 vaccination in Brazil.
Funding None.
Research in context
Evidence before this study
Evidence before this study COVID-19 is still very active, having spread to over two hundred countries and caused more than one million deaths worldwide. Its current situation requires large-scale studies to assess the impact of preexisting comorbidities, symptoms, and socioeconomic issues regarding mortality rate, especially where lack of control is evident. We searched PubMed, Google Scholar, medRxiv, and bioRxiv on Dec 12, 2020, for studies published in English or Brazilian Portuguese, estimating the impact of several risk factors in COVID-19 prognosis. We used the search terms “Brazil” or “risk factors” or “ethnicity” or “cohort” or “diabetes mellitus” or “mortality” or “symptoms” or “comorbidities”, and related synonyms, combined with “SARS-CoV-2” or “COVID-19”. Many pre-existing conditions have shown to directly impact patient prognosis, out of which cancer, chronic kidney disease, chronic obstructive pulmonary disease, cardiovascular disease, obesity, and diabetes, among others, are well established in SARS-CoV-2 infection severeness. Some studies reported an increased death risk for non-white Brazilians, but no large scale cohort analyzing the impact of one or more associated risk factors in younger Brazilians patients were found.
Added value of this study
Added value of this study We found that the impact of having one or two or more risk factors on mortality are progressively higher in ages (60, 80], (40, 60], (20, 40], and (0, 20], compared with people of the same age interval without comorbidities. We also found that young brown individuals with diabetes, as well as black ethnicity on its own, are population subgroups at remarkably higher risk for severe COVID-19 in Brazil. Furthermore, advanced age, usage of ventilatory support, admission to intensive care units, multiple respiratory symptoms, and diagnosis previous to hospitalization were associated with higher death odds. As protective factors, we found hospitalization duration of (4, 7] days and illness onset to hospitalization over 6 days.
Implications of all the available evidence
Implications of all the available evidence We identified multiple epidemiological profiles associated with death risk in different age ranges in Brazilian COVID-19 hospitalized patients. These findings unveil that a large part of Brazilian working-age population is at a higher risk for SARS-CoV-2 death, a neglected situation that is further exacerbating inequalities, leading to a striking sociodemographic and economic impact. We hope that our analysis aids patient risk stratification, hospital management optimization, and public policy determination, including prioritization for COVID-19 vaccination in Brazil.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm all relevant ethical guidelines have been followed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
DATA SHARING SRAG data is publicly available on the Ministry of Health of Brazil website. The analysis source code will be available upon request to the authors.
